Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NIH awards $2.3M to Thetis for colitis work
January 2018
SHARING OPTIONS:

BRANFORD, Conn.—Biopharmaceutical company Thetis Pharmaceuticals has received a Fast-Track Small Business Innovation Research grant from the National Institutes of Health that will provide up to $2.3 million for the development of TP-317 as an oral therapy for ulcerative colitis. TP-317 delivers Resolvin E1 (RvE1), a naturally occurring lipid that manages the resolution of inflammation and the body’s return to normal after an immune response. Preclinical efficacy studies are underway in collaboration with Dr. Daniel Rosenberg, a professor of medicine at the University of Connecticut, and thus far, preclinical work in colitis has shown that TP-317 and RvE1 can control disease activity at small doses.
 
Gary Mathias, co-founder and CEO of Thetis, said: “TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system. The grant will support the advancement of this promising, potential new therapy into the clinic.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.